U.S. Markets closed

Medivation weakness a buying opportunity, says Brean Capital

Brean Capital would be buyers in weakness of Medivation following Q4 results. The firm believes its long term thesis is intact and see approval of Xtandi in the pre-chemo setting in early 2014. Shares are Buy rated with a $100 price target.